Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors by Seini Moimoi | Nov 15, 2024 | Portfolio News
Epirium Bio Presented Late-Breaking Preclinical Data of MF-300 (15-PGDH Enzyme Inhibitor) at the Gerontological Society of America Annual Scientific Meeting 2024 by Seini Moimoi | Nov 13, 2024 | Portfolio News
Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors by Seini Moimoi | Nov 12, 2024 | Portfolio News
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) by Seini Moimoi | Nov 12, 2024 | Portfolio News
Bolt Medical Announces Completion of The RESTORE ATK and RESTORE BTK Pivotal Studies Investigating the Unique Bolt Intravascular Lithotripsy System by Seini Moimoi | Nov 4, 2024 | Portfolio News
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 by Seini Moimoi | Oct 26, 2024 | Portfolio News
